Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG Phipps
- Development stage
- Unknown
- Lead developer
- Henry Phipps Institute
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical, Intradermal
01
Overview
BCG Phipps is a specific substrain of the Bacillus Calmette-Guérin (BCG) vaccine, derived from *Mycobacterium bovis*. It is classified as an evolutionarily 'late' substrain, characterized by the genetic deletion of the Region of Differentiation 2 (RD2) and the presence of surface lipids such as phthiocerol dimycocerosates (PDIM) and phenolic glycolipids (PGL), which are associated with its virulence and immunogenic profile. Clinically, BCG Phipps is utilized as a biological response modifier for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC), particularly carcinoma in situ. Its mechanism of action involves the induction of a localized, robust immune response within the bladder wall, leading to the production of pro-inflammatory cytokines like interleukin-6 (IL-6) and interleukin-8 (IL-8) and the recruitment of immune effector cells to eliminate tumor cells. While used in oncology and tuberculosis prevention, research suggests its immunostimulatory potency may vary compared to other BCG substrains like Connaught or Russian.
- Other names
- Phipps strainBCG Phipps substrainBacillus Calmette-Guérin Phipps
02
Targets
TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on BCG Phipps.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG Phipps.